[1]乔斌超 贾永平.小干扰RNA降脂药物英克司兰研究进展[J].心血管病学进展,2024,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]
　QIAO Binchao,JIA Yongping.Small Interfering RNA Lipid-Lowering Drug of Inclisiran[J].Advances in Cardiovascular Diseases,2024,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]
点击复制

小干扰RNA降脂药物英克司兰研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年6期
页码:
525
栏目:
综述
出版日期:
2024-06-25

文章信息/Info

Title:
Small Interfering RNA Lipid-Lowering Drug of Inclisiran
作者:
乔斌超 1 贾永平 2
(1.山西医科大学第一临床医学院,山西 太原 030001;2.山西医科大学第一医院心内科,山西 太原 030001)
Author(s):
QIAO Binchao1; JIA Yongping2
(1.The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,Shanxi,China2. Department of Cardiology,The First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi,China)
关键词:
小干扰RNA; 英克司兰; 前蛋白转化酶枯草溶菌素9; 低密度脂蛋白胆固醇
Keywords:
Small interfering RNA; Inclisiran; Proprotein convertase subtilisin/kexin type 9; Low density lipoprotein cholesterol
DOI:
10.16806/j.cnki.issn.1004-3934.2024.06.011
摘要:
英克司兰是一种新型的小干扰RNA降脂药物，通过靶向递送至肝脏，在肝细胞内特异性抑制前蛋白转化酶枯草溶菌素9的合成，从而降低低密度脂蛋白胆固醇水平。目前FDA和国家药品监督管理局已经正式批准英克司兰上市。现从英克司兰的作用机制、临床应用有效性及安全性等方面进行综述，以期为降脂治疗提供参考。
Abstract:
Inclisiran is a novel small interfering RNA lipid-lowering drug that through targeted delivery to the liver,specifically inhibits the synthesis of the proprotein convertase subtilisin/kexin type 9 in liver cells,thereby reducing low density lipoprotein cholesterol levels. At present,the FDA and the National Medical Products Administration have officially approved the marketing of inclisiran. This article provides a review of the mechanism of action,clinical application efficacy and safety of inclisiran,in order to provide reference for lipid-lowering treatment

参考文献/References:

[1] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38 (3):237-271.

[2] Wo?owiec ?,Osiak J,Wo?owiec A,et al. Inclisiran-safety and effectiveness of small interfering RNA in inhibition of PCSK9[J]. Pharmaceutics,2023,15(2):323.

[3] Friedrich M,Aigner A. Therapeutic siRNA:state-of-the-art and future perspectives[J]. BioDrugs,2022,36(5):549-571.

[4] Zhang MM,Bahal R,Rasmussen TP,et al. The growth of siRNA-based therapeutics:updated clinical studies[J]. Biochem Pharmacol,2021,189:114432.

[5] Crooke ST,Witztum JL,Bennett CF,et al. RNA-targeted therapeutics[J]. Cell Metab,2018,27(4):714-739.

[6] Traber GM,Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies[J]. J Pharmacol Exp Ther,2023,384(1):133-154.

[7] Weng Y,Xiao H,Zhang J,et al. RNAi therapeutic and its innovative biotechnological evolution[J]. Biotechnol Adv,2019,37(5):801-825.

[8] Chernikov IV,Ponomareva UA,Chernolovskaya EL. Structural modifications of siRNA improve its performance in vivo[J]. Int J Mol Sci,2023,24(2):956.

[9] Abosalha AK,Ahmad W,Boyajian J,et al. A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications[J]. Expert Opin Drug Discov,2023,18(2):149-161.

[10] Akinc A,Maier MA,Manoharan M,et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs[J]. Nat Nanotechnol,2019,14(12):1084-1087.

[11]Wilkinson MJ,Bajaj A,Brousseau ME,et al. Harnessing RNA interference for cholesterol lowering:the bench-to-bedside story of?inclisiran[J]. J Am Heart Assoc,2024,13(6):e032031.

[12] Carugo S,Sirtori CR,Gelpi G,et al. Updates in small interfering RNA for the treatment of dyslipidemias[J]. Curr Atheroscler Rep,2023,25(11):805-817.

[13] Ranasinghe P,Addison ML,Dear JW,et al. Small interfering RNA:discovery,pharmacology and clinical development-an introductory review[J]. Br J Pharmacol,2023,180(21):2697-2720.

[14] German CA,Shapiro MD. Small interfering RNA therapeutic inclisiran:a new approach to targeting PCSK9[J]. BioDrugs,2020,34(1):1-9.

[15] Tromp TR,Stroes ESG,Hovingh GK. Gene-based therapy in lipid management:the winding road from promise to practice[J]. Expert Opin Investig Drugs,2020,29(5):483-493.

[16] McDougall R,Ramsden D,Agarwal S,et al. The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human[J]. Drug Metab Dispos,2022,50(6):781-797.

[17] Ray KK,Landmesser U,Leiter LA,et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15):1430-1440.

[18] Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels:one-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol,2019,4(11):1067-1075.

[19] 国家老年医学中心,中国医药教育协会老年药学专业委员会,中国药学会医院药学专业委员会,等. 小干扰RNA降脂药物药学专家共识[J]. 中国医院药学杂志,2024,44(1):9-17.

[20] Fitzgerald K,Frank-Kamenetsky M,Shulga-Morskaya S,et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,single-blind,placebo-controlled,phase 1 trial[J]. Lancet,2014,383(9911):60-68.

[21] Fitzgerald K,White S,Borodovsky A,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med,2017,376(1):41-51.

[22] Ray KK,Troquay RPT,Visseren FLJ,et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3):results from the 4-year open-label extension of the ORION-1 trial[J]. Lancet Diabetes Endocrinol,2023,11(2):109-119.

[23] Raal FJ,Kallend D,Ray KK,et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med,2020,382(16):1520-1530.

[24] Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.

[25] Wright RS,Ray KK,Raal FJ,et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol,2021,77(9):1182-1193.

[26] Ray KK,Raal FJ,Kallend DG,et al. Inclisiran and cardiovascular events:a patient-level analysis of phase III trials[J]. Eur Heart J,2023,44(2):129-138.

[27] Wright RS,Raal FJ,Koenig W,et al. ORION-8:long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients[C]. Amsterdam:European Society of Cardiology(ESC),2023.

[28] Wright RS,Koenig W,Landmesser U,et al. Safety and tolerability of inclisiran for?treatment of hypercholesterolemia in?7 clinical trials[J]. J Am Coll Cardiol,2023,82(24):2251-2261.

[29] Huo Y,Lesogor A,Lee CW,et al. Efficacy and safety of inclisiran in Asian patients：results from ORION-18[J]. JACC Asia,2023,4(2):123-134.

[30] 霍勇,李勇,韩雅君,等. 英克司兰钠注射液在中国大陆ASCVD或ASVCD高危受试者中的有效性和安全性:ORION-18研究亚组分析[C]. 北京:第34届长城心脏病学大会,2023,Poster GW34-e0796.

相似文献/References:

[1]王咏春 高红梅 刘芳 朱希瑶 徐茂青.治疗高血压的新靶点：血管紧张素原[J].心血管病学进展,2021,(7):619.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.011]
　WANG Yongchun,GAO Hongmei,LIU Fang,et al.A New Target for Treatment of Hypertension: Angiotensinogen[J].Advances in Cardiovascular Diseases,2021,(6):619.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.011]
[2]张小芳?张冬颖.RNA干扰疗法降低脂蛋白a的临床研究进展[J].心血管病学进展,2023,(7):622.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.011]
　ZHANG Xiaofang,ZHANG Dongying.Clinical Research of RNA Interference Therapy in Reducing Lipoprotein (a)[J].Advances in Cardiovascular Diseases,2023,(6):622.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.011]
[3]康雅隆 齐鸿飞 葛腾 彭涛 余婷 剧嘉欣 程草草 关芳 余湖斌 王海芳.小干扰RNA降脂药物英克司兰在心血管疾病中的研究进展[J].心血管病学进展,2024,(6):529.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.012]
　KANG Yalong,QI Hongfei,GE Teng,et al.siRNA Lipid-Lowering Drug Inclisiran in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(6):529.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.012]

更新日期/Last Update: 2024-07-26